Study to Identify and Characterize Bacteria Causing Acute Otitis Media in Young Children in Turkey
This study has been withdrawn prior to enrollment.
Sponsor:
GlaxoSmithKline
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01031329
First received: December 10, 2009
Last updated: August 2, 2012
Last verified: August 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to identify and characterize the bacteria causing complicated Acute Otitis Media episode in children >= 3 months to < 5 years in Turkey.
| Condition | Intervention |
|---|---|
|
Complicated Acute Otitis Media |
Procedure: Tympanocenthesis and urine collection |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Prospective |
| Official Title: | Identification and Characterization of the Bacteria Causing Acute Otitis Media (AOM) Episodes in Young Children in Turkey |
Resource links provided by NLM:
Further study details as provided by GlaxoSmithKline:
Primary Outcome Measures:
- Occurrence of bacterial pathogens isolated from middle ear fluid samples. [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Occurrence of bacterial serotypes. [ Designated as safety issue: No ]
- Antimicrobial susceptibility of bacteria isolated from middle ear fluid samples collected from sub-groups of complicated acute otitis media cases. [ Designated as safety issue: No ]
- Occurrence of treatment failure of acute otitis media and of recurrent acute otitis media. [ Designated as safety issue: No ]
- Occurrence of bacteria in acute otitis media cases vaccinated with a pneumococcal vaccine. [ Designated as safety issue: No ]
- Occurrence of spontaneous otorrhoea. [ Designated as safety issue: No ]
Biospecimen Retention: Samples Without DNA
Middle ear fluid and urine.
| Enrollment: | 0 |
| Study Start Date: | November 2012 |
| Estimated Study Completion Date: | February 2014 |
| Estimated Primary Completion Date: | February 2014 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
Complicated Acute otitis media Group
This group was divided into 3 sub-groups.
|
Procedure: Tympanocenthesis and urine collection
Fluid using needle aspiration is obtained from middle ear fluid. Urine is collected using a urine bag.
|
Eligibility| Ages Eligible for Study: | 3 Months to 5 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Subjects aged >= 3 months and < 5 years, diagnosed as having complicated acute otitis media on routine clinical care in the study hospitals.
Criteria
Inclusion Criteria:
- Age: >= 3 months and < 5 years at the time they are seen by the paediatrician. The subject becomes ineligible on the fifth birthday.
- Signs, symptoms, and conditions:
- One of the functional or general signs of otalgia ,conjunctivitis, fever and either
- Paradise's criteria or
- Spontaneous otorrhoea of less than 24 hours.
- Subjects if classified as recurrent acute otitis media or treatment failure as described below:
- Recurrent acute otitis media: Defined as a subject who has an episode of acute otitis media representing the third new episode within the past 6 months, or the fourth new episode within the past year.
- Treatment failure: Defined as a subject who was diagnosed with acute otitis media and received antibiotic treatment from a physician, but is still symptomatic 48-72 hours after initiation of the treatment. As with other acute otitis media cases, the onset of signs or symptoms should have been within 72 hours prior to the initial visit to the physician.
- Written informed consent obtained from parent or guardian prior to study start.
Exclusion Criteria:
- Hospitalised during the diagnosis of acute otitis media or during treatment.
- Otitis externa, or otitis media with effusion.
- Presence of a transtympanic aerator.
- Systemic antibiotic treatment received for a disease other than acute otitis media in the 72 hours prior to enrolment.
- Receiving antimicrobial prophylaxis for recurrent acute otitis media.
- Provision of antibiotic by paediatrician at the enrolment visit prior to the sampling of the middle ear fluid or spontaneous otorrhoea.
- Patients that are on antibiotics for acute otitis media, and are clinically improving.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01031329
Locations
| Turkey | |
| GSK Investigational Site | |
| Adana, Turkey, 1330 | |
| GSK Investigational Site | |
| Adana, Turkey | |
| GSK Investigational Site | |
| Ankara, Turkey | |
| GSK Investigational Site | |
| Ankara, Turkey, 6100 | |
| GSK Investigational Site | |
| Istanbul, Turkey | |
| GSK Investigational Site | |
| Istanbul, Turkey, 34280 | |
| GSK Investigational Site | |
| Izmir, Turkey, 35100 | |
Sponsors and Collaborators
GlaxoSmithKline
Investigators
| Study Director: | GSK Clinical Trials | GlaxoSmithKline |
More Information
No publications provided
| Responsible Party: | GlaxoSmithKline |
| ClinicalTrials.gov Identifier: | NCT01031329 History of Changes |
| Other Study ID Numbers: | 111339 |
| Study First Received: | December 10, 2009 |
| Last Updated: | August 2, 2012 |
| Health Authority: | Turkey: Ministry of Health |
Additional relevant MeSH terms:
|
Otitis Otitis Media Ear Diseases Otorhinolaryngologic Diseases |
ClinicalTrials.gov processed this record on June 17, 2013